

FORM PTO-1390 (Modified)
(REV 11-98)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES

344-P-16-USA

DESIGNATED/ELECTED OFFICE (DO/EO/US)

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

CONCERNING A FILING UNDER 35 U.S.C. 371

09/509237

INTERNATIONAL APPLICATION NO.
PCT/US98/22022INTERNATIONAL FILING DATE
19 OCT., 1998PRIORITY DATE CLAIMED
NONE

TITLE OF INVENTION

METHODS AND COMPOSITIONS FOR IN SITU FORMATION OF PROTECTIVE AND/OR
MEDICATED FILMS ON BODY TISSUE

APPLICANT(S) FOR DO/EO/US

DRUMMOND, WILLIAM H.
ROSE, SETH D.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☐ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ Certificate of Mailing by Express Mail
20. ☒ Other items or information:

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY - INDEPENDENT INVENTOR;
 VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY - SMALL BUSINESS CONCERN;
 DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION;
 COPY OF EXECUTED ASSIGNMENT - (RECORDED IN PCT APPLICATION).

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.53) 09/509237	INTERNATIONAL APPLICATION NO. PCT/US98/22022	ATTORNEY'S DOCKET NUMBER 344-P-16-USA
--	--	---

21. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

- ☒ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO **\$970.00**
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO **\$840.00**
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO **\$690.00**
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) **\$670.00**
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) **\$96.00**

ENTER APPROPRIATE BASIC FEE AMOUNT =**\$970.00**

Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).

\$0.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	6 - 20 =	0	x \$18.00
Independent claims	6 - 3 =	3	x \$78.00

\$0.00**\$234.00**Multiple Dependent Claims (check if applicable). ☐**\$0.00****TOTAL OF ABOVE CALCULATIONS =****\$1,204.00**

Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). ☒

\$602.00**SUBTOTAL =****\$602.00**

Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).

\$0.00**TOTAL NATIONAL FEE =****\$602.00**

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). ☐

\$0.00**TOTAL FEES ENCLOSED =****\$602.00**

Amount to be: refunded	\$
charged	\$

☒ A check in the amount of **\$602.00** to cover the above fees is enclosed.

☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.

☐ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. _____ A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

**WILLIAM H. DRUMMOND
DRUMMOND & DUCKWORTH
4590 MacARTHUR BLVD., SUITE 500
NEWPORT BEACH, CA 92660**

SIGNATURE

William H. Drummond

NAME

20,590

REGISTRATION NUMBER

March 20, 2000

DATE

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS (37 CFR 1.9(f) AND 1.27 (c)) - SMALL BUSINESS CONCERN**

Docket No.
344-P-16-USA

Serial No.

Filing Date

Patent No.

Issue Date

Applicant/ **WILLIAM H. DRUMMOND**
Patentee: **SETH D. ROSE**

Invention: **METHOD AND COMPOSITIONS FOR IN SITU FORMATION OF PROTECTIVE
AND/OR MEDICATED FILMS ON BODY TISSUE**

I hereby declare that I am:

- ☐ the owner of the small business concern identified below:
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN: **ZILA, INC.**

ADDRESS OF CONCERN: **5227 NORTH SEVENTH STREET, PHOENIX, AZ 85014-2800**

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the above identified invention described in:

- ☐ the specification filed herewith with title as listed above.
☒ the application identified above.
☐ the patent identified above.

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed on the next page and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☐ no such person, concern or organization exists.
☒ each such person, concern or organization is listed below.

FULL NAME ZILA, INC.
 ADDRESS 5227 NORTH SEVENTH STREET, PHOENIX, ARIZONA 85014-2800

☐ Individual ☒ Small Business Concern ☐ Nonprofit Organization

FULL NAME _____
 ADDRESS _____

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

FULL NAME _____
 ADDRESS _____

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

FULL NAME _____
 ADDRESS _____

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.


NAME OF PERSON SIGNING: JANICE L. BACKUS, VICE PRESIDENT

TITLE OF PERSON SIGNING _____

OTHER THAN OWNER: 5227 NORTH SEVENTH STREET, PHOENIX, AZ 85014-2800

ADDRESS OF PERSON SIGNING: _____

SIGNATURE: _____



DATE: 3.3.00

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS (37 CFR 1.9(f) AND 1.27 (b)) - INDEPENDENT INVENTOR**

Docket No.
344-P-16-USA

Serial No.

Filing Date

Patent No.

Issue Date

Applicant/ **WILLIAM H. DRUMMOND**
Patentee: **SETH D. ROSE**

Invention: **METHOD AND COMPOSITIONS FOR IN SITU FORMATION OF PROTECTIVE
AND/OR MEDICATED FILMS ON BODY TISSUE**

As a below named inventor, I hereby declare that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, to the Patent and Trademark Office with regard to the invention entitled above and described in:

- ☐ the specification to be filed herewith.
☒ the application identified above.
☐ the patent identified above.

I have not assigned, granted, conveyed or licensed and am under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who could not be classified as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☐ No such person, concern or organization exists.
☒ Each such person, concern or organization is listed below.

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities (37 CFR 1.27)

FULL NAME **ZILA, INC.**

ADDRESS **5227 NORTH SEVENTH STREET, PHOENIX, ARIZONA 85014-2800**
☐ Individual☒ Small Business Concern☐ Nonprofit Organization

FULL NAME

ADDRESS

☐ Individual☐ Small Business Concern☐ Nonprofit Organization

FULL NAME

ADDRESS

☐ Individual☐ Small Business Concern☐ Nonprofit Organization

FULL NAME

ADDRESS

☐ Individual☐ Small Business Concern☐ Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF INVENTOR WILLIAM H. DRUMMOND

SIGNATURE OF INVENTOR 

DATE: Feb 24, 2000

NAME OF INVENTOR SETH D. ROSE

SIGNATURE OF INVENTOR 

DATE: March 13, 2000

NAME OF INVENTOR _____

SIGNATURE OF INVENTOR _____

DATE: _____

NAME OF INVENTOR _____

SIGNATURE OF INVENTOR _____

DATE: _____

NAME OF INVENTOR _____

SIGNATURE OF INVENTOR _____

DATE: _____

NAME OF INVENTOR _____

SIGNATURE OF INVENTOR _____

DATE: _____

NAME OF INVENTOR _____

SIGNATURE OF INVENTOR _____

DATE: _____

NAME OF INVENTOR _____

SIGNATURE OF INVENTOR _____

DATE: _____

NAME OF INVENTOR _____

SIGNATURE OF INVENTOR _____

DATE: _____

NAME OF INVENTOR _____

SIGNATURE OF INVENTOR _____

DATE: _____

-1-

**METHOD AND COMPOSITIONS FOR *IN SITU*
FORMATION OF PROTECTIVE AND/OR MEDICATED
FILMS ON BODY TISSUE**

5 This invention relates to methods for *in situ*
formation of protective films on body tissue.

 In addition, the invention relates to compositions
that form medicated films *in situ* on body tissue.

10 In another respect, the invention concerns methods
and compositions for *in situ* formation of protective
and/or medicated films on body tissue.

15 According to another aspect, the invention provides
methods and compositions for *in situ* formation of films
on body tissue, films that provide slow or sustained
release of topical medicaments and/or provide a
protective coating for the underlying tissue.

20 Pharmacologists have long sought to provide methods
and compositions for *in situ* formation of protective
and/or medicated films on body tissues, such that a
protective film could be formed and maintained at
25 specific locations on or inside a human or animal body.
The underlying body tissue may have a cut, abrasion,

-2-

wound or lesion, or may be infected. Such a protective film could prevent insult of the underlying wound or lesion by external substances, germs, etc. or prevent infection of surrounding healthy tissue by preventing spread of the infection, e.g., by viral shedding.

Alternatively, the body tissue, to which a medicated film is applied, may be healthy, but there it is desired to administer a drug for absorption through the skin or the surface of an internal organ. In particular, medications, such as topical anesthetics, corticosteroids, bactericidal and viricidal sterilization agents and the like are difficult to maintain in proper contact with various body tissues, because of physical movement of the underlying or adjacent tissues or abrasion of such tissues by the movement of wound dressings, clothing, etc. It is especially difficult to maintain protective and/or medicated films on wet or moist tissues, such as mucosal tissues, and upon other body tissues which exude or secrete blood, perspiration, or other aqueous body fluids.

In the case of mucosal tissue, it is considered practically impossible to reliably maintain a protective or medicinal treatment composition at the treatment site.

-3-

The mucosal tissues are glabrous and initially wet which interferes with such compositions at their intended locations.

5 The use of topical anesthetics for reducing pain is known. For example, commercially-available preparations containing benzocaine or corticosteroids and various thickeners are widely used. However, these do not form coherent, persistent films in the mouth and are easily displaced from the ulcer site by saliva and physical movement of the surrounding tissues.

10 An intra-oral ointment base for use in the oral cavity has been provided which consists essentially of sodium carboxymethylcellulose and pectin. However, such ointments are not considered sufficiently persistent to solve the basic problem of forming a protective film over an oral lesion and/or maintaining a topical analgesic or other medication in contact with an ulcer for up to
15 several hours.

20 Topical adhesive dosages for mucosal ulcers or lesions have also been proposed in the form of a two-phase tablet having a pre-formed adhesive peripheral film

- 4 -

of hydroxypropylcellulose (hereafter "HPC") with a medication carried in an oleaginous core of cocoa butter which is next to the underlying tissue. This device was reported to adhere to the mucosa of dogs for thirty minutes to six hours.

Mixtures of HPC and polyvinyl acetate have been proposed as film-forming carriers for medications, but, according to our knowledge, no use of such systems for intra-oral application of topical medicines has resulted.

Precast films of HPC carrying analgesics and antibiotics has been reported anecdotally for the treatment of pain of leukoplakia.

Alkylcellulose and/or cellulose ether compounds have been used as thickeners or ointment bases for a wide variety of medicaments. For example, hydroxyethylcellulose (hereafter, "HEC") and/or HPC was used to form a gel for application of the topical acne medications of U.S. Patent No. 4,244,948 to Boghosian, et al. HEC was used to form a water soluble lotion or gel in a cold sore/fever blister medication sold as "Kank-A®", a registered trademark of Blistex, Inc. A water-

-5-

soluble film formed of HPC was used as the carrier for a bactericide, in a bovine teat-dip composition in U.S. Patent No. 4,434,181 to Marks, et al.

5 Heretofore, it was known that the pain associated with cold sores, fever blisters and recurrent aphthous stomatitis (RAS) lesions, was temporarily alleviated by the medicinal composition of the Tinnell U.S. Patent 4,381,296, in an alcohol-esterified HPC-water carrier. 10 However, clinical tests did not show that the pain reduction was due to the action of the medications, but that the principal analgesic effect was believed to be due to a formation of a protective film which formed over the lesions. This film, which persisted on the lesion 15 for several hours, acted as a barrier to insults by air, foods, saliva, etc. This composition was first sold by Zila Pharmaceuticals, Inc. in the early 1980s under the trademark "HERPAWAY" and later sold, until 1993, under the trademark "ZILACTIN"®.

20 Later, in the mid-1980s, it was discovered that the film forming ability of HERPAWAY and ZILACTIN® compositions was due to partial esterification of the HPC component by the medicinal components of Tinnell '296,

-6-

rather than by simple deposition of unmodified HPC material *per se* upon the lesion, upon vaporization of the alcoholic solvent.

5 Later, a gel-like product has been marketed which is believed to contain hydroxyethylcellulose (HEC) salicylic acid, ethyl alcohol and benzocaine. The composition does form a film on body tissue, but there are indications that it causes irritation of the underlying tissue. It is not known if the salicyloyl ester of HEC is present or is formed in this composition.

10 It was also known (Stoughton, *Arch. Dermatol.* 1962, 86, 608-610 ; Stoughton, *Arch. Dermatol.* 1985, 121, 63-15 67) to potentiate the effects of topical medications by first applying a quantity of the medicament to body tissue (epidermis), usually in a lotion or gel carrier, and then covering the medicament-treated site with a pre-formed impermeable elastic film or membrane. The 20 membrane maintained the medicament in contact with the tissue to which it was applied and prevented physical dislocation of the medication by body fluids, e.g., by washing the medication away during normal bathing, dislocation by movement of the underlying tissue and/or

-7-

by dislocation by abrasion of the medicament by clothing or contact of the other body tissues or objects.

Until our invention, there was only one known composition which would provide the same medication-
potentiating results as those described by Stoughton, but which achieved that result by direct *in situ* formation of a medicated film on body tissue by applying a liquid composition containing the drug. This composition was described by Pomerantz in U.S. Patents 5,081,158 and 5,081,157. The composition was a liquid (gel) comprising partially-esterified HPC in a volatile solvent (the original HERPAWAY/ZILACTIN), plus a separate medicinal component, i.e., separate and in addition to any other medicaments, if any, which might have been dispensed from the original HERPAWAY/ZILACTIN compositions. Upon application of these compositions to body tissue and "drying" of the liquid (gel) composition (by volatilization of the solvent), these compositions formed an adherent, coherent *in situ*-deposited medicated film containing the separate medication on the body tissue, even on wet mucosal tissue, and effectively dispensed the separate medication to the underlying body tissue.

-8-

Accordingly, later versions of the original ZILACTIN® product, sold since 1993-94, contained separate medicinal components, namely benzocaine (ZILACTIN®-B) and benzyl alcohol (ZILACTIN®), components which are recognized as effective for the treatment of cold sores and fever blisters.

Subsequent unpublished research has confirmed that the original ZILACTIN® films included very small quantities of HPC esterified by salicylic and/or tannic acid components. This conclusion was supported by published literature, authored by Landoll, confirming that normally water-soluble HPC is rendered insoluble in water, if modified by attachment of very small quantities (as low as 0.9-1.3 wt %) of hydrophobic groups (long-chain hydrocarbons), through ether-linkages, to the HPC backbone. The insoluble hydrophobe-modified polymer, is however, soluble in aqueous ethanol. J.Polym.Sci., Polymer Chemistry Ed., 20, 443-455 (Wiley, 1982).

Well prior to the publication of the Landoll paper, it was known that hydrophobic groups impart water-insolubility to chemical substances, whereas hydrophilic groups impart water-solubility. In particular, the

-9-

water-solubility of polymers is strongly dependent on the hydrophilicity and hydrophobicity of the repeating units of the polymer. For example, it is known from the prior art that the copolymer poly(vinyl acetate-co-vinyl alcohol) contains both a hydrophilic substituent (hydroxyl group) and a hydrophobic substituent (the methyl group of acetate), and at greater than 30 mole % of the methyl-group-containing monomer, the copolymer is insoluble in water. It was also known from the Landoll paper, that hydrophobic modification of hydrophilic (i.e., water-soluble) polymers such as HPC renders the modified polymer water insoluble at body temperatures, even at low levels of introduction of the hydrophobic modifier. For example, the introduction of only approximately three hydrophobic groups (e.g., C₁₂) per polymer chain of HPC (MW 50,000) renders the modified polymer insoluble in water. Theoretical explanations of this phenomenon envisage the formation of three-dimensional networks of polymer molecules formed by the hydrophobic bonding, or "association", of the limited number of hydrophobic groups attached to the polymer chains. These "liaisons" between molecules serve to greatly increase the effective molecular weight of the polymer, dramatically reducing its solubility. Increased

-10-

viscosity is also observed for aqueous solutions of less extensively modified polymer.

We have now discovered that the principle of hydrophobic modification of polymers is effectively employed to produce new liquid compositions for forming films *in situ* upon body tissues. These compositions are formed from a polymer and an agent ("interaction agent") that interacts with the polymer to form a product ("interaction product") which is substantially insoluble at normal body temperatures in water or aqueous body fluids, but which is soluble in a nontoxic volatile solvent. Application of this interaction product, dissolved in a non-toxic volatile solvent, will result in the *in situ* formation of a film of the interaction product on body tissue, including moist surfaces such as mucosal tissues, upon evaporation of the volatile solvent, and the film is persistent because it is substantially insoluble in aqueous-based body fluids. Depending on the chemistry of the specific method used to prepare the interaction product, it can either be prepared separately and then dissolved in a suitable volatile solvent, or, alternatively, if the reactants used to prepare the interaction product, and reaction

-11-

byproducts, are pharmacologically acceptable, the interaction product can be prepared *in situ* in our liquid compositions. The interaction between the polymer and the interaction agent can occur during manufacture or storage of the liquid compositions, during application of the liquid compositions to body tissues, or even during "drying" of the liquid compositions by vaporization of the volatile solvent or during only some or all such times.

Furthermore, because substantially the same result is obtained by copolymerization of monomers with hydrophilic and hydrophobic groups, those copolymer compositions and methods of preparation are included as specific embodiments of the general principles of this invention. In this case the agent which interacts (copolymerizes) with the polymer to form the water-insoluble interaction product is itself another polymer, copolymer, modified polymer or modified copolymer.

Briefly, then, in accordance with our invention, we provide a method of forming a film *in situ* on body tissue. Our method comprises the steps of (a) applying to body tissue a liquid composition which includes a non-

-12-

toxic volatile solvent and a solubility-modified polymer,
other than an esterified HPC (of the Pomerantz patents),
or a copolymer, which is soluble in the solvent, but
insoluble in body fluids; and (b) separating the solvent
from the liquid composition, to form a persistent film.
The film can act merely as a protective "bandage" film
which excludes air, body fluids and other foreign
materials from an underlying lesion, or which prevents
the escape of substances, e.g., viruses, from a lesion
underlying the film, which may cause spread of an
infection to or irritation of surrounding healthy tissue.
These liquid compositions of the invention may also
contain additional medicinal components (i.e., in
addition to those components, if any, of the film-forming
compositions which may have an incidental medicinal
effect) which are effectively dispensed from these liquid
compositions and/or from the *in-situ*-deposited films
formed therefrom.

As will be apparent to those skilled in the art the
liquid compositions of the invention may also include
additive components for modifying the characteristics of
the liquid compositions and/or for facilitating the
manufacture of the compositions, including, without

-13-

limiting the generality thereof, flavors, plasticizers, dermal penetrants, preservatives, as well as other "secondary" solvents which are used to dissolve the interaction agent(s) and other additive components. If any of these additive components have any incidental medicinal effects, it is intended that the term "separate medicinal component means a medicinal component in addition to those present in the primary solvent, in the modified polymer or copolymer and in the additive components.

The method of the invention also contemplates the steps of (a) forming an interaction product by interaction of a polymer (which may include HPC) and at least one interaction agent, other than an esterification agent (as in the Pomerantz '158 patent), which interacts with the polymer (and possibly with other components of the interaction mixture), to form an interaction product. The interaction agent is soluble in a solvent, but insoluble in body fluids; (b) solublizing the interaction product in the solvent; and (c) forming a film *in situ* on body tissue by applying the solvent solution of the interaction product to body tissue and (d) separating the solvent from the liquid composition. As previously

-14-

disclosed, the interaction product can be separately
manufactured and then solublized in the solvent or,
alternatively, the interaction product can be formed *in*
situ, during manufacture and/or storage of the liquid
composition or during the application-drying of the
liquid composition upon body tissue, or both.

Our invention also contemplates a liquid composition
which forms a medicated film *in situ* upon body tissue,
comprising: (a) a solvent; (b) an interaction product
formed by interaction between a polymer and an agent
other than an esterification agent, which interaction
product is soluble in the solvent, but insoluble in body
fluids; and (c) a medicinal component, in addition to any
other medicament, if any, in the polymer, the interaction
agent(s), the interaction product, and any other
functional additives in the composition. Also the
invention contemplates such a liquid composition,
containing such a separate medicament, but in which the
substrate polymer is a polymer other than a lower
hydroxyalkyl-substituted cellulose, in which case, the
interaction agent can include esterification agents.

-15-

The solvent for the interaction product is preferably a volatile solvent, such as, for example volatile polar solvents. As used herein, the term "volatile" solvent means a solvent which evaporates (vaporizes) from the liquid compositions, after they are applied to the body tissue, at a rate which is sufficient to cause formation of the film on the body tissue within a practical length of time, e.g., 30 seconds - 5 minutes. This permits application of liquid compositions by persons with limited medical skills, e.g., technicians or even the patients themselves. The application site can be substantially immobilized, and abrasion of the site by other body parts, clothing, etc., and irrigation by body fluids can normally be suspended or eliminated during this suitable short period of time, to permit formation of the film. After the film forms on the tissue, the film is sufficiently adherent and coherent, such that it is persistent at the application site for a time sufficient to permit the film to perform its intended function, i.e., to temporarily relieve pain, by forming a physical barrier over the application site, and/or to permit the film to hold a separate medication against the tissue (lesion, wound, etc.), for a sufficient period of time to achieve practical therapeutic effects, e.g., from

-16-

15 - 30 minutes to as high as upwards of 4 - 6 hours.

5 The particular solvent for forming the liquid
composition is selected for its ability to dissolve the
components of the liquid composition, the ability to
maintain the interaction product in solution or
suspension until application of the composition to the
treatment site and the ability to be rapidly separated
from the composition after application to the body
10 tissue, e.g., by vaporization, extraction, etc. as well
as for its non-toxic characteristics when the composition
is applied in the amount and for the time necessary to
form a protective and/or medicated film. Obviously, the
solvent should not be toxic to the body in the quantities
15 and contact times employed and it must be chemically
compatible with the other components of the liquid
compositions, i.e., these solvents are those which are
"pharmacologically acceptable". Suitable solvents will
be readily identified by those skilled in the art having
20 a regard for the disclosures herein, e.g., volatile polar
solvents which are medically compatible with body tissue
and which are chemically compatible with the other
components of the liquid compositions, i.e., such
solvents which are "pharmacologically acceptable".

-17-

Advantageously, the solvent is a lower alkyl alcohol, e.g., preferably ethyl alcohol or isopropyl alcohol. Ethyl alcohol is preferred when the film is to be deposited in the oral cavity, whereas isopropyl alcohol is suitable for use in depositing films on the skin.

The term "liquid" composition includes liquids, the viscosity of which ranges from that of a "runny" liquid, to a viscous lotion or even to a spreadable self-supporting gel. Advantageously, in order to permit more accurate application of liquid to a specific treatment site, e.g., a fever blister or cold sore or small wound, the liquid composition is preferably in the form of a spreadable gel which can be conveniently filled into flexible dispensing tubes which can be squeezed to dispense the gel directly onto the application site or onto an applicator, such as the tip of a finger or a swab, from which it is applied to the body tissue.

-18-

The term "soluble" (in the solvent) means that the components of the liquid composition are either completely dissolved in or at least substantially uniformly dissolved or suspended or substantially uniformly dispersed in the liquid composition, such that the liquid composition is sufficiently stable to withstand separation of one or more of its components until the liquid composition can be applied to the body tissue. This may vary from a period of time of only a few minutes (in the case of the liquid compositions which are to be applied soon after formulation), to up to several years (for products sold through normal ethical or over-the counter channels). Extended shelf-life can be determined by accelerated aging tests which are well known and accepted in the art.

The term "insoluble" in body fluids means that the interaction product is sufficiently resistant to solubilization or other film-destructive actions of body fluids, e.g., saliva, perspiration, blood, and the like, to enable the *in situ* deposited film to remain adherent to the body tissue and sufficiently coherent to allow the film to perform its intended function, i.e., to act as a physical protective coating for the underlying tissue,

-19-

and/or to dispense the separate medication therefrom.

The term "non-toxic" means that a component is not injurious to body tissues or body functions at the concentrations employed and/or for the time that the component is in contact with the tissue.

The term "separating" the solvent from the liquid composition means the removal of the solvent from the liquid composition, after application to body tissue, by any suitable technique, such that the interaction product is deposited as a coherent, adherent film on the tissue, for example, by simply air-drying the applied liquid composition, by accelerated air-drying (as by heating the applied liquid composition with hot air or a heat lamp) or by preferentially extracting the solvent from the liquid composition by gently irrigating the application site with an aqueous solvent which dissolves part or all of the volatile solvent and simultaneously assists in precipitating the water-insoluble interaction product and/or separate medication, as a coherent, persistent film.

-20-

The terms forming a film "*in situ*" or film-forming "*in situ*" (upon body tissue) means that the film autogenously forms on the body tissue upon separation of the solvent component of the liquid compositions, as distinguished from films which are pre-formed, e.g., by casting, extrusion or compression or thermal molding, and thereafter applied to the body tissue.

The term "upon" body tissue does not exclude the possibility that an intermediate film of another chemical or physical nature may lie between at least parts of the interaction product film and the body tissue. For example, the application of a liquid composition containing ethyl alcohol as the solvent to moist mucosal tissue causes more or less immediate denaturation of saliva and/or tissue proteins which underlie the *in situ* deposited film described herein. Such an intermediate denatured-protein film does not appear to degrade the effectiveness of the interaction product film, either as a protective barrier or as carrier for a separate medication. In fact, such an intermediate layer or material appears to actually assist in adhesion of the *in situ*-deposited interaction product film to the underlying tissue.

-21-

According to the presently preferred embodiments of the invention, the interaction product component of the compositions of the invention is present in the composition in an amount of from about 1-10% by weight of the final composition. The proportion of the interaction product in the composition affects the time required for the composition to air dry and form a tough adhesive film. At lower contents of the interaction product, the compositions dry more slowly, but the resultant film is more coherent and abrasion-resistant. At higher contents, the film forms more quickly by air drying, but the resultant film is less coherent and adhesive owing to the fact that the portion of the film at the surface of the applied composition and at the body tissue surface dry at different rates.

At present, we prefer to employ enough of the interaction product and solvent in the final composition to yield an easily-applied gel which dries to form the *in situ*-deposited film in a practical length of time, as distinct from a runny liquid or lotion which is difficult to maintain on the intended treatment site for a time sufficient to form the *in situ*-deposited film and which may take too long to form the film. Likewise, the amount

-22-

of the interaction product should not be so great or the amount of solvent so small as to form a stiff gel, which may be difficult to dispense or to spread on the application site. This optimum quantity may vary depending on the exact chemical composition of the interaction product and the nature of the other components of the final compositions. This optimum quantity can, however, be readily determined by persons skilled in the art, without undue experimentation, having regard for this disclosure.

The invention can be visualized as using an interaction product, comprising a three-part molecule composed of a polymer, a "linker", and a hydrophobic group, schematically represented as:

(polymer)-(linker)-(hydrophobic group)

wherein the linker may or may not contain atoms that were originally part of the polymer and/or the hydrophobic group. These major constituents of the interaction product molecule consist of:

-23-

(1) a polymer, including synthetic polymers, natural polymers, and synthetically modified natural polymers, including homopolymers, as well as block, alternating, and random copolymers.

(2) a "linker" that may consist of organic functional groups that are known to join differing domains of complex organic molecules, including but not limited to esters ($\text{O}=\text{C}-\text{O}$) and their sulfur derivatives [i.e., thio ($\text{S}=\text{C}-\text{O}$), thiolo ($\text{O}=\text{C}-\text{S}$), and dithio ($\text{S}=\text{C}-\text{S}$) derivatives], ethers ($-\text{O}-$) and their thio derivatives ($-\text{S}-$), urethanes [$\text{O}-(\text{C}=\text{O})-\text{N}$] and their thio derivatives (e.g., xanthates), carbonates [$\text{O}-(\text{C}=\text{O})-\text{O}$] and their thio derivatives, amides ($\text{O}=\text{C}-\text{N}$) and imides and their thio derivatives, ureas [$\text{N}-(\text{C}=\text{O})-\text{N}$] and their thio derivatives, amines ($\text{C}-\text{N}$), imines ($\text{C}=\text{N}$), acetals and hemiacetals [$\text{RCH}(\text{OR}')(\text{OR}'')$ and $\text{RCH}(\text{OR}')(\text{OH})$] and their thio derivatives, ketals and hemiketals [$\text{RR}'\text{C}(\text{OR}'')(\text{OR}''')$ and $\text{RR}'\text{C}(\text{OR}'')(\text{OH})$] and their thio derivatives, sulfonates [$-\text{S}(=\text{O})_2-\text{O}$], sulfinates [$-\text{S}(=\text{O})-\text{O}$], sulfonamides [$-\text{S}(=\text{O})_2-\text{N}$], sulfinamides [$-\text{S}(=\text{O})-\text{N}$], disulfides ($-\text{S}-\text{S}-$) and their various mono- and polyoxides, sulfoxides [$\text{R}-\text{S}(=\text{O})-\text{R}'$],

-24-

sulfones $[R-S(=O)_2-R']$, carbon-carbon single or
 multiple bonds, alcohols $[RC(OH)R']$, ketones
 $[R-(C=O)-R']$ and thioketones $[R-(C=S)-R']$, phosphate
 esters $[RO-P(=O)(O^-)-OR']$ and $RO-P(=O)(OR')(OR'')$,
 5 phosphamides $[RO-P(=O)(O^-)-NR']$ and
 $RO-P(=O)(OR')(NR'')$ and $RO-P(=O)(NR')(NR'')$ and
 $O=P(NR)(NR')(NR'')$ and their less substituted
 analogues, e.g., $RO-P(=O)(NR')(NH_2)$, phosphonate
 esters $[R-P(=O)(O^-)-OR']$, and phosphonamides
 10 $[R-P(=O)(O^-)-NR']$ and $R-P(=O)(NR')NR''$ and their less
 substituted derivatives], phosphinate esters
 $[R-P(=O)-OR']$, phosphinamides $[R-P(=O)-NR']$, or
 combinations thereof,

15 wherein, the various R, R', R'', and R''' groups are the
 polymer and/or hydrophobic groups being linked.

(3) a hydrophobic group that may principally derive
 its hydrophobicity from a hydrocarbon group,
 20 including saturated and unsaturated hydrocarbon
 chains (e.g., terpenes) and rings (i.e., cycloalkyl)
 and combinations thereof (e.g., steroids), which may
 contain one or more heteroatoms in the chains and/or
 rings, or fats, oils, waxes, or from a haloalkyl


-25-

group, such as a partially or entirely fluoro-substituted alkyl chain [e.g., $(CF_2)_n(CF_3)$] or ring or combination thereof, such groups typically exhibiting greater hydrophobicity than the comparable-length parent unsubstituted hydrocarbon, or from an aromatic or aralkyl group (i.e., combined aromatic and aliphatic constituents), or heterocyclic groups (e.g., furyl, thienyl), or from a silicone (e.g., dimethylsiloxane unit or units) or other heteroatom-containing hydrophobic group, and including any other group with generally recognized hydrophobic character.


Specific embodiments of the invention, which are chosen to illustrate the practice of the invention and which are not intended as limitations on the scope thereof, include:

(1) HPC (HPC-OH), a synthetically modified natural polymer, hydrophobically modified by covalent attachment of a long hydrocarbon chain via a urethane linkage to a hydroxyl group of the HPC, as for instance through the reaction of HPC-OH with octadecyl isocyanate, shown below:

-26-




(2) Carboxymethylcellulose, a synthetically modified natural polymer, hydrophobically modified by covalent attachment of a hydrocarbon chain via an amide linkage, for instance through the reaction of the carboxymethylcellulose with a condensing agent and N-hydroxysuccinimide to produce an active ester [CMC-C(=O)-X], followed by treatment with a long-chain amine (e.g., octadecylamine), shown below:




(3) Poly(vinyl alcohol-co-vinyl acetate), a synthetic vinyl polymer, hydrophobically modified by covalent attachment of a hydrocarbon chain via an ester linkage, as for instance through the reaction of the polymer with a fatty acid chloride in the presence of a base, shown below (in which block, random, or alternating copolymer is not meant to be implied by the structural representation):

-27-



(4) Polyiminodiacetamide, a synthetic polyether, hydrophobically modified by covalent attachment of a perfluoroalkyl chain via a sulfonamide linkage, as for instance through the reaction of the polymer-bound amine functional groups with perfluoro-1-octanesulfonyl fluoride, shown below:



-28-

described above may be carried out in homogeneous
solution by use of a suitable solvent or by emulsion
techniques, in which a polymer-containing phase is mixed
with the hydrophobic reactant-containing phase for
linkage formation in the two-phase mixture.

The following specific examples are presented to
illustrate the preparation of compositions which are
useful in accordance with various embodiments of the
invention. They are not intended to indicate or limit
the scope of the invention, which is set forth only in
the appended claims.

-29-

Example 1

Synthesis of hydrophobically modified HPC

A urethane linkage is employed in the
5 hydrophobically modified polymer described in this
example.

To a solution of 5.0 g of HPC (molecular weight
50,000 and molar substitution = 3.0) in 575 mL of
10 tetrahydrofuran (or an appropriate volume of another
suitably unreactive solvent, such as dioxane or pyridine)
under an inert atmosphere, is slowly added with stirring
a solution of octadecyl isocyanate in 50 mL of the same
solvent. To achieve approximately 1% bound modifier, the
15 amount of octadecyl isocyanate should be 0.05 g in excess
of the amount destroyed by any moisture contained in the
HPC. After a 1-day reaction time, the reaction mixture
is cautiously poured into cold water to quench the
reaction and precipitate the product. The product is
20 collected by filtration or centrifugation, washed with
water, and air dried. The degree of substitution is
determined by nitrogen analysis. Variation of the amount
of modifier bound, if required to optimize the water
solubility of the interaction product, can be achieved by

-30-

variation of the reaction time, temperature, and/or ratio of the reactants.

Example 2

Synthesis of hydrophobically modified carboxymethylcellulose

An amide linkage is employed in the hydrophobically modified polymer described in this example.

To a suspension of 5 g of carboxymethylcellulose in 25 mL of dioxane containing 0.1 g of N-hydroxysuccinimide is added 3 g of 1,3-dicyclohexylcarbodiimide. The reaction mixture is stirred for 4 hours to allow formation of the active ester of the polymer-bound carboxyl groups. The polymer is collected by filtration, washed with dioxane, and transferred to a solution of 0.05 g of octadecylamine in 25 mL of dioxane, to achieve approximately 1% bound modifier. After a 1-day reaction time, the reaction mixture is poured into aqueous acid to quench the reaction, solubilize any remaining amine, and precipitate the product. The product is collected by centrifugation, washed with water, and air dried. The degree of substitution is determined by nitrogen

-31-

analysis. To optimize the water solubility of the modified polymer, some variation of the amount of modifier bound may be required, which can be achieved by variation of the reaction time, temperature, and/or the ratio of the reactants.

Example 3

Synthesis of hydrophobically modified poly(vinyl alcohol-co-vinyl acetate)

An ester linkage is employed in the hydrophobically modified polymer described in this example.

To 5 g of poly(vinyl alcohol-co-vinyl acetate) whose vinyl acetate content is less than 30 mole %, prepared by the controlled saponification of poly(vinyl acetate), is added 50 mL of pyridine, and the mixture is stirred overnight. To this stirred mixture is added 0.057 g of palmitoyl chloride dissolved in 5 mL of pyridine, to achieve approximately 1% bound modifier. After a reaction time of 1 day, the mixture is added to aqueous hydrochloric acid to precipitate the product. The product is collected by filtration, washed with water,

-32-

and redissolved in ethyl alcohol and reprecipitated with water, for purification, and air dried. The degree of substitution is determined by saponification and fatty acid analysis. For optimal modified polymer solubility, variation of the amount of modifier bound can be achieved by variation of the reaction time, temperature, and/or ratio of the reactants.

Example 4

Synthesis of hydrophobically modified polyiminodiacetamide

A sulfonamide linkage is employed in the hydrophobically modified polymer described in this example. To a solution of 5 g of polyiminodiacetamide in 25 mL of toluene is added 0.05 g of perfluoro-1-octanesulfonyl fluoride dissolved in 5 mL of toluene, to achieve approximately 1% bound modifier. After a reaction time of 1 day, the mixture is cautiously added to cold water to quench the reaction and precipitate the product. Finely divided silicic acid may advantageously be added as catalyst. After 2 hours at 60 deg C, the reaction mixture is cooled, and the product is collected

-33-

by filtration, washed with water, and air dried. The degree of substitution is determined by fluorine and sulfur analyses. For optimal modified polymer water-solubility properties, variation of the amount of modifier bound is achieved by variation of the reaction time, temperature, and/or ratio of the reactants.

Example 5

Synthesis of hydrophobically modified hydroxyethylcellulose (HEC)

An ester linkage is employed in the hydrophobically modified polymer in this example.

To 5 g of HEC in 50 mL of pyridine is added 0.057 g of palmitoyl chloride dissolved in 5 mL of pyridine, to achieve approximately 1% bound modifier. After a reaction time of 1 day, the mixture is added to aqueous hydrochloric acid to precipitate the product. The product is collected by centrifugation, washed with water, and redissolved in isopropyl alcohol and reprecipitated with water, for purification, and air dried. The degree of substitution is determined by

-34-

saponification and fatty acid analysis. For optimal modified polymer water-solubility properties, variation of the amount of modifier bound can be achieved by variation of the reaction time, temperature, and/or ratio of the reactants.

Example 6

Preparation of hydrophobically modified
HEC, during manufacture/storage of a
film-forming composition

In this example hydrophobically modified HEC via an ester linkage is prepared during the manufacture/storage of the final film-forming composition.

To 1 g of HEC in 5 g of polyethylene glycol is added 0.035 g of octadecenylsuccinic anhydride and 0.015 g of triethanolamine.

After a reaction time of 1 day, to the mixture is added 13.95 g of aqueous ethanol to destroy any unreacted anhydride and to dissolve the modified HEC. For adjustment of the degree of substitution to obtain

-35-

optimal film water-solubility properties, the amount of HEC, the anhydride, triethanolamine, and polyethylene glycol, as well as reaction time, reaction temperature, and pH can be varied.

10 wt.% benzocaine is added to the dissolved modified HEC. The resultant composition is shelf-stable and functions effectively to treat the pain of cold sores, fever blisters and RAS lesions, by a combination of the protective "bandage" film formed *in situ* after application of the composition to the site of lesions and the anaesthetic effect of the benzocaine. The film remains in place on the lesion for several hours.

Example 7

Other film-forming compositions containing
a separate medication

Therapeutically effective quantities of various topical medicines are incorporated into ethanol solutions containing 2-8 wt % of the modified polymers of Examples 1-6. The resulting mixtures are shelf-stable and are topically applied to body tissue and air-dried, forming

-36-

coherent, adherent films containing the medicines. The medicine migrates to the treatment site to effectively accomplish the desired therapeutic result.

Anesthetics

Benzocaine
Dyclonine hydrochloride
Hexylcaine hydrochloride
Pramoxine hydrochloride
Butamben picrate
Tetracaine hydroiodide

Anti-Inflammatory Agents

Hydrocortisone acetate
Betamethasone valerate
Triamcinolone acetonide
Fluocinonide
Dexamethasone
Methylprednisone acetate

-37-

Antibiotics

5 Clindamycin
Erythromycin
Meclocycline sulfosalicylate
Tetracycline
Chlorhexidine
Neomycin
10 Polymyxin B sulfate
Bacitracin
Sulfadoxine

Antifungal Agents

15 Clotrimazole
Miconazole
Nystatin
Acyclovir
20 Interferon
Vidarabine
Betadine

Miscellaneous Topical Agents

25 Salicylic acid
Isotretinoin
Aloe Vera
Alclomethasone dipropionate
30 Caprylic acid
Lindane

Having described the invention in such terms as to
35 enable one skilled in the art to understand and practice
it and, having identified the presently preferred best
modes of the invention, WE CLAIM:

CLAIMS:

-38-

1. The method of forming a film *in situ* upon
body tissue, comprising:

(a) applying to body tissue a liquid composition,
comprising

(1) a solvent,

(2) a polymer, other than an esterified hydroxy-
loweralkyl cellulose, which is soluble in said
solvent, but insoluble in body fluids;

and

(b) separating said solvent from said liquid
composition.

-39-

2. The method of forming a film *in situ* upon
body tissue, comprising:

(a) applying to body tissue a liquid composition,
comprising

(1) a solvent,

(2) a polymer, other than a hydroxy-loweralkyl
cellulose, which is soluble in said
solvent, and

(3) at least one interaction agent other than
an esterification agent, which interacts
with said polymer to form an interaction
product which is soluble in said solvent,
but insoluble in body fluids;

and

(b) separating said solvent from said liquid
composition.

-40-

3. The method of forming a film *in situ* upon
body tissue, comprising:

(a) applying to body tissue a liquid composition,
comprising

(1) a solvent,

(2) a polymer, which is soluble in said solvent,
and

(3) at least one interaction agent, other than an
esterification agent, which interacts with said
polymer to form an interaction product, which
is soluble in said solvent, but insoluble in
body fluids;

and

(b) separating said solvent from said liquid
composition.

-41-

4. A composition which forms a medicated film *in situ* upon body tissue, comprising:

- (a) a first solvent;
- (b) a polymer, other than a hydroxy-loweralkyl cellulose, which is soluble in said first solvent;
- (c) at least one interaction agent, which interacts to form an interaction product, said interaction product being soluble in said first solvent, but insoluble in body fluids; and
- (d) at least one additive component, selected from the group consisting of flavors, plasticizers, dermal penetrants, preservatives and second solvents for said interaction agent and additive component;
- (e) a medicinal component, in addition to any other medicament, if any, in components (a), (b), (c), and (d).

-42-

5. A composition which forms a medicated film *in situ* upon body tissue, comprising:

- (a) a first solvent;
- (b) a hydrophobically-modified polymer, which is soluble in said first solvent, but insoluble in body fluids, said modified polymer being formed by interaction with at least one interaction agent, other than an esterification agent, said modified polymer being soluble in said first solvent, but insoluble in body fluids;
- (c) at least one additive component, selected from the group consisting of flavors, plasticizers, dermal penetrants, preservatives and second solvents, if any, for said interaction agent and additive component;
- (d) a separate medicinal component, in addition to any medicaments, if any, in components (a), (b) and (c).

-43-

6. A composition which forms a medicated film *in situ* upon body tissue, comprising:

(a) a first solvent;

(b) a modified polymer other than a modified hydroxy loweralkyl cellulose, which is soluble in said first solvent, but insoluble in body fluids, said modified polymer being formed by interaction of a polymer with at least one interaction agent, said modified polymer being soluble in said first solvent, but insoluble in body fluids;

(c) at least one additive component, selected from the group consisting of flavors, plasticizers, dermal penetrants, preservatives and second solvents, if any, for said interaction agent and additive components;

(d) a separate medicinal component, in addition to any medicaments, if any, in components (a), (b) and (c).

Docket No.
344-P-16-USA

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**METHOD AND COMPOSITIONS FOR IN SITU FORMATION
OF PROTECTIVE AND/OR MEDICATED FILMS ON BODY TISSUE**

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on October 19, 1998 as United States Application No. or PCT International
Application Number PCT/US98/22022
and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

PCT/US98/22022

OCT. 19, 1998

PENDING

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*

WILLIAM H. DRUMMOND, REG. 20,590

DAVID G. DUCKWORTH, REG. 39,516

Send Correspondence to: **DRUMMOND & DUCKWORTH**
4590 MacArthur Blvd., Suite 500
Newport Beach, CA 92660

Direct Telephone Calls to: *(name and telephone number)*
William H. Drummond (949) 724-1255

Full name of sole or first inventor Seth D. Rose	
Sole or first inventor's signature <i>Seth D. Rose</i>	Date <i>March 13, 2000</i>
Residence 613 E. Balboa Drive, Tempe, Arizona 85282, USA <i>AZ</i>	
Citizenship USA	
Post Office Address Same as above	

Full name of second inventor, if any William H. Drummond	
Second inventor's signature <i>William H. Drummond</i>	Date <i>Mar 20, 00</i>
Residence 104 Via Havre, Newport Beach, California 92663 <i>CA</i>	
Citizenship USA	
Post Office Address Same as above	